ABNCoV2
ABNCoV2 is a COVID-19 vaccine candidate developed by Bavarian Nordic.[1][2][3][4]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
References
- "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". Bavarian Nordic. 8 March 2021. Retrieved 13 April 2021.
- "Safety and Tolerability of ABNCoV2 (COUGH-1)". ClinicalTrials.gov. 9 April 2021. NCT04839146. Retrieved 13 April 2021.
- "Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021.
- "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects". ClinicalTrials.gov. 14 October 2021. NCT05077267. Retrieved 14 October 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.